Products/Services Used | Details | Operation |
---|---|---|
Peptide Library Services> | Published in partnership with the Sealy Institute for Vaccine Sciences using the influenza A virus (A/California/07/2009) HA peptide pool and SARS-CoV-2 RBD peptide pool (peptides are 15mers, with 11 amino acid overlaps, Genscript) at 1.5 µg/ml per peptide. | Get A Quote |
As the world continues to experience the COVID-19 pandemic, seasonal influenza remain a cause of severe morbidity and mortality globally. Worse yet, coinfection with SARS-CoV-2 and influenza A virus (IAV) leads to more severe clinical outcomes. The development of a combined vaccine against both COVID-19 and influenza is thus of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we developed and characterized a novel mRNA vaccine encoding the HA antigen of influenza A (H1N1) virus, termed ARIAV. Then, ARIAV was combined with our COVID-19 mRNA vaccine ARCoV, which encodes the receptor-binding domain (RBD) of the SARS-CoV-2 S protein, to formulate the final combine... More